Next Article in Journal
Prospects in the Application of Photodynamic Therapy in Oral Cancer and Premalignant Lesions
Previous Article in Journal
Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(9), 82; doi:10.3390/cancers8090082

Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials

Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON N1G 2W1, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Hui-Wen Lo
Received: 27 June 2016 / Revised: 9 August 2016 / Accepted: 15 August 2016 / Published: 1 September 2016
View Full-Text   |   Download PDF [697 KB, uploaded 1 September 2016]   |  

Abstract

The Wnt signaling pathway is intricately involved in many aspects of development and is the root cause of an increasing number of diseases. For example, colorectal cancer is the second leading cause of death in the industrialized world and aberration of Wnt signaling within the colonic stem cell is the cause of more than 90% of these cancers. Despite our advances in successfully targeting other pathways, such as Human Epidermal Growth Factor Receptor 2 (HER2), there are no clinically relevant therapies available for Wnt-related diseases. Here, we investigated where research activities are focused with respect to Wnt signaling modulators by searching the United States Patent and Trade Office (USPTO) for patents and patent applications related to Wnt modulators and compared this to clinical trials focusing on Wnt modulation. We found that while the transition of intellectual property surrounding the Wnt ligand-receptor interface to clinical trials is robust, this is not true for specific inhibitors of β-catenin, which is constitutively active in many cancers. Considering the ubiquitous use of the synthetic T-cell Factor/Lymphoid Enhancer Factor (TCF/Lef) reporter system and its success in identifying novel modulators in vitro, we speculate that this model of drug discovery does not capture the complexity of in vivo Wnt signaling that may be required if we are to successfully target the Wnt pathway in the clinic. Notwithstanding, increasingly more complex models are being developed, which may not be high throughput, but more pragmatic in our pursuit to control Wnt signaling. View Full-Text
Keywords: Wnt; β-catenin; TOPflash; SUPERTOPFlash; HEK293; screen; inhibitors; patents; cancer; clinical trials Wnt; β-catenin; TOPflash; SUPERTOPFlash; HEK293; screen; inhibitors; patents; cancer; clinical trials
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lu, B.; Green, B.A.; Farr, J.M.; Lopes, F.C.; Van Raay, T.J. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. Cancers 2016, 8, 82.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top